Please login to the form below

Not currently logged in
Email:
Password:

Eltrombopag gets FDA priority review

GlaxoSmithKline was granted a priority review for its drug Promacta by the US Food and Drugs Administration on March 3.

GlaxoSmithKline (GSK) was granted a priority review for its drug Promacta by the US Food and Drugs Administration (FDA) on March 3.

Promacta (eltrombopag) could be the first oral thrombocytopenic (TPO) receptor for short-treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP).

Now the priority has been given, the FDA is expected to render a decision on the New Drug Application (NDA) for the investigational compounds within six months.

Dr Paolo Paoletti, senior vice president of the Oncology Medicine Development Centre at GSK, said: "The FDA designation of our submission for priority review is very encouraging and brings us closer to offering physicians and their patients eltrombopag."

"Our goal for eltrombopag is to make available a targeted therapy in oral form for patients to help raise their platelet counts without having to suppress the immune system."

Europe could benefit from this new medication as GSK plans to make a Marketing Authorisation Application (MAA) in 2008 for eltrombopag, which in the EU is marketed as Revolade.

Eltrombopag is now also being considered as a potential long-term treatment for chronic ITP in addition to thrombocytopenia associated with hepatitis C.

3rd March 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics